FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078414230> ?p ?o ?g. }

• W2078414230 endingPage "1312" @default.
• W2078414230 startingPage "1307" @default.
• W2078414230 abstract "No AccessJournal of UrologyAdult urology1 Apr 2007Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study Julie N. Graff, Motomi Mori, Hong Li, Mark Garzotto, David Penson, Arnold L. Potosky, and Tomasz M. Beer Julie N. GraffJulie N. Graff Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon Oregon Health and Science University Cancer Institute, Portland, Oregon More articles by this author , Motomi MoriMotomi Mori Biostatistics Shared Resource, Portland, Oregon More articles by this author , Hong LiHong Li Biostatistics Shared Resource, Portland, Oregon More articles by this author , Mark GarzottoMark Garzotto Division of Urology, Oregon Health and Science University, Portland, Oregon Urology Section, Portland Veterans Affairs Medical Center, Portland, Oregon More articles by this author , David PensonDavid Penson Departments of Urology and Preventive Medicine, University of Southern California/Norris Cancer Center, Los Angeles, California Financial interest and/or other relationship with Dendreon, Sanofi-Aventis, Pfizer and Boehringer-Ingelheim. More articles by this author , Arnold L. PotoskyArnold L. Potosky Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland More articles by this author , and Tomasz M. BeerTomasz M. Beer Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon Oregon Health and Science University Cancer Institute, Portland, Oregon More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2006.11.054AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Primary androgen suppression therapy for clinically localized prostate cancer is increasingly common in the United States despite a lack of supportive evidence for its use. We determined which demographic and clinical factors predict overall and cancer specific survival with this treatment strategy in patients enrolled in the Prostate Cancer Outcomes Study. Materials and Methods: In 1994 to 1995 the Prostate Cancer Outcomes Study recruited 3,533 men diagnosed with prostate cancer. Clinical and treatment information was abstracted from medical records and demographic characteristics were obtained from patient surveys 6, 12, 24 and 60 months after diagnosis. Overall and cancer specific mortality was analyzed through December 2002 using the Kaplan-Meier method and Cox regression. Results: A total of 276 patients had organ confined (cT1-2) prostatic adenocarcinoma and received primary androgen suppression therapy within 1 year of diagnosis. Median followup for censored patients was 7.6 years (range 1.1 to 8.1). Five-year overall and cancer specific survival was 66% (95% CI 59–72) and 91% (95% CI 86–94), respectively. Independent predictors of shorter overall survival were patient age 75 years or older, prostate specific antigen 20 ng/ml or greater, Gleason score 7 or greater and abnormal digital rectal examination. Gleason score 7 or greater, prostate specific antigen 20 ng/ml or greater and a low comorbidity index were independent predictors of shorter cancer specific survival. Conclusions: The use of primary androgen suppression therapy in the Prostate Cancer Outcomes Study data set resulted in 91% 5-year cancer specific survival. Advanced age, and factors that reflect tumor burden and biology were predictive of overall survival, while cancer specific survival was predicted by tumor factors and the burden of comorbid conditions. A nomogram for predicting overall survival at 5 years was constructed. References 1 : Cancer statistics, 2006. CA Cancer J Clin2006; 56: 106. Google Scholar 2 : Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Canc Netw2005; 3: S29. Google Scholar 3 : Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst2001; 93: 1864. Google Scholar 4 : The current state of hormonal therapy for prostate cancer. CA Cancer J Clin2002; 52: 154. Google Scholar 5 : Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med1997; 337: 295. Crossref, Medline, Google Scholar 6 : Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys2001; 49: 937. Google Scholar 7 : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 1781. Crossref, Medline, Google Scholar 8 : Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int2002; 90: 561. Google Scholar 9 : Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer2005; 103: 1615. Google Scholar 10 : National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst2003; 95: 981. Google Scholar 11 : Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer2006; 106: 1708. Google Scholar 12 : Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int2005; 96: 503. Google Scholar 13 : Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst1999; 91: 1719. Google Scholar 14 : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998; 280: 969. Crossref, Medline, Google Scholar 15 : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med2005; 352: 1977. Google Scholar 16 : High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA1992; 267: 2191. Google Scholar 17 : Determining cause of death in prostate cancer: are death certificates valid?. J Natl Cancer Inst2001; 93: 1822. Google Scholar 18 : Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst2002; 94: 430. Google Scholar 19 : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med2005; 352: 154. Google Scholar 20 : Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol2000; 163: 1743. Link, Google Scholar © 2007 by American Urological AssociationFiguresReferencesRelatedDetails Volume 177Issue 4April 2007Page: 1307-1312 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordsnomogramsprostateandrogen antagonistsmortalityprostatic neoplasmsMetricsAuthor Information Julie N. Graff Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon Oregon Health and Science University Cancer Institute, Portland, Oregon More articles by this author Motomi Mori Biostatistics Shared Resource, Portland, Oregon More articles by this author Hong Li Biostatistics Shared Resource, Portland, Oregon More articles by this author Mark Garzotto Division of Urology, Oregon Health and Science University, Portland, Oregon Urology Section, Portland Veterans Affairs Medical Center, Portland, Oregon More articles by this author David Penson Departments of Urology and Preventive Medicine, University of Southern California/Norris Cancer Center, Los Angeles, California Financial interest and/or other relationship with Dendreon, Sanofi-Aventis, Pfizer and Boehringer-Ingelheim. More articles by this author Arnold L. Potosky Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland More articles by this author Tomasz M. Beer Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon Oregon Health and Science University Cancer Institute, Portland, Oregon More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2078414230 created "2016-06-24" @default.
• W2078414230 creator A5014068004 @default.
• W2078414230 creator A5021979132 @default.
• W2078414230 creator A5026692219 @default.
• W2078414230 creator A5039922522 @default.
• W2078414230 creator A5046800754 @default.
• W2078414230 creator A5048477205 @default.
• W2078414230 creator A5088481479 @default.
• W2078414230 date "2007-04-01" @default.
• W2078414230 modified "2023-09-24" @default.
• W2078414230 title "Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study" @default.
• W2078414230 cites W1963592300 @default.
• W2078414230 cites W1983414502 @default.
• W2078414230 cites W1990050184 @default.
• W2078414230 cites W1997732940 @default.
• W2078414230 cites W2013136992 @default.
• W2078414230 cites W2032194590 @default.
• W2078414230 cites W2058818042 @default.
• W2078414230 cites W2066899660 @default.
• W2078414230 cites W2072031700 @default.
• W2078414230 cites W2090963388 @default.
• W2078414230 cites W2113868668 @default.
• W2078414230 cites W2117792530 @default.
• W2078414230 cites W2120993630 @default.
• W2078414230 cites W2156569873 @default.
• W2078414230 cites W2161964583 @default.
• W2078414230 cites W2316095838 @default.
• W2078414230 cites W2337912524 @default.
• W2078414230 cites W4233182856 @default.
• W2078414230 cites W4245951364 @default.
• W2078414230 doi "https://doi.org/10.1016/j.juro.2006.11.054" @default.
• W2078414230 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17382720" @default.
• W2078414230 hasPublicationYear "2007" @default.
• W2078414230 type Work @default.
• W2078414230 sameAs 2078414230 @default.
• W2078414230 citedByCount "18" @default.
• W2078414230 countsByYear W20784142302012 @default.
• W2078414230 countsByYear W20784142302013 @default.
• W2078414230 countsByYear W20784142302014 @default.
• W2078414230 countsByYear W20784142302017 @default.
• W2078414230 countsByYear W20784142302020 @default.
• W2078414230 crossrefType "journal-article" @default.
• W2078414230 hasAuthorship W2078414230A5014068004 @default.
• W2078414230 hasAuthorship W2078414230A5021979132 @default.
• W2078414230 hasAuthorship W2078414230A5026692219 @default.
• W2078414230 hasAuthorship W2078414230A5039922522 @default.
• W2078414230 hasAuthorship W2078414230A5046800754 @default.
• W2078414230 hasAuthorship W2078414230A5048477205 @default.
• W2078414230 hasAuthorship W2078414230A5088481479 @default.
• W2078414230 hasConcept C121608353 @default.
• W2078414230 hasConcept C126322002 @default.
• W2078414230 hasConcept C126894567 @default.
• W2078414230 hasConcept C143998085 @default.
• W2078414230 hasConcept C2776235491 @default.
• W2078414230 hasConcept C2777911890 @default.
• W2078414230 hasConcept C2778559712 @default.
• W2078414230 hasConcept C2780192828 @default.
• W2078414230 hasConcept C29456083 @default.
• W2078414230 hasConcept C2994186761 @default.
• W2078414230 hasConcept C3019894029 @default.
• W2078414230 hasConcept C71315377 @default.
• W2078414230 hasConcept C71924100 @default.
• W2078414230 hasConceptScore W2078414230C121608353 @default.
• W2078414230 hasConceptScore W2078414230C126322002 @default.
• W2078414230 hasConceptScore W2078414230C126894567 @default.
• W2078414230 hasConceptScore W2078414230C143998085 @default.
• W2078414230 hasConceptScore W2078414230C2776235491 @default.
• W2078414230 hasConceptScore W2078414230C2777911890 @default.
• W2078414230 hasConceptScore W2078414230C2778559712 @default.
• W2078414230 hasConceptScore W2078414230C2780192828 @default.
• W2078414230 hasConceptScore W2078414230C29456083 @default.
• W2078414230 hasConceptScore W2078414230C2994186761 @default.
• W2078414230 hasConceptScore W2078414230C3019894029 @default.
• W2078414230 hasConceptScore W2078414230C71315377 @default.
• W2078414230 hasConceptScore W2078414230C71924100 @default.
• W2078414230 hasIssue "4" @default.
• W2078414230 hasLocation W20784142301 @default.
• W2078414230 hasLocation W20784142302 @default.
• W2078414230 hasOpenAccess W2078414230 @default.
• W2078414230 hasPrimaryLocation W20784142301 @default.
• W2078414230 hasRelatedWork W1971192623 @default.
• W2078414230 hasRelatedWork W1980188241 @default.
• W2078414230 hasRelatedWork W1980245127 @default.
• W2078414230 hasRelatedWork W2003917043 @default.
• W2078414230 hasRelatedWork W2106003470 @default.
• W2078414230 hasRelatedWork W2127440557 @default.
• W2078414230 hasRelatedWork W2348716247 @default.
• W2078414230 hasRelatedWork W2418385838 @default.
• W2078414230 hasRelatedWork W2590008096 @default.
• W2078414230 hasRelatedWork W2897445903 @default.
• W2078414230 hasVolume "177" @default.
• W2078414230 isParatext "false" @default.
• W2078414230 isRetracted "false" @default.
• W2078414230 magId "2078414230" @default.
• W2078414230 workType "article" @default.